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Spray-On Special Effects
Mendel Biotechnology Uses Chemical Genetics
to Help Plants Cope with StressAgriculture has always been at the
mercy of the elements and blessed
by the gods. But instead of praying
for rain, farmers in the near future
may use chemical genetics to help
crops better cope with heat, cold,
and drought. Chemical genetics
uses small molecules to modulate
biochemical pathways to discover
how gene products function. If, in
plants, this method is implemented
on transcription factors that regu-
late gene expression, it can comple-
ment selective breeding or genetic
modification of crops, or, in some
cases, replace them altogether. For
instance, resistance to drought can
be instilled by selectively breeding
the most tolerant plant in your
patch, by genetically modifying the
plant, or by switching on the bio-
chemical pathway that makes the
plant transpire less water in a heat
spell.
Research in chemical genetics in
the late 90s was pioneered by Stuart
Schreiber, Ph.D., professor and chair
of the Department of Chemistry at
Harvard and director of the Chemical
Biology Program at the Broad Insti-
tute. Schreiber and others use small
molecules to study biochemical
pathways predominantly in yeast
and mammalian cells. High through-
put screening of chemical libraries
against plant targets has only been
done in the last five or six years.
‘‘It’s been exhilarating to watch and
to learn from the pioneers of plant
biology who had the vision to explore
plant circuitry with small molecules,’’
said Schreiber. ‘‘Plants are ideal in
many respects to dissect using this
approach. In the process of revealing
underlying principles, agents with
considerable promise in agriculture
are being revealed.’’
At the heart of chemical genetics
is the idea is that if you change a spe-
cific protein by attaching a small
molecule, either covalently or non-covalently, you either activate the
protein or disable it. The molecule
acts like a switch. The end result is
the alteration of a measurable phe-
notype. For instance, if you discover
a molecule that binds to a particular
protein, and, by doing so, find it
enhances the organism’s sensitivity
to heat, then by tracing the genes
that encode the proteins involved
in that biochemical chain, you may
discover the genetic basis for heat
tolerance. This can be a challenge,
as molecules can bind to multiple
protein targets, and determining
the key protein or pathway is
crucial.
Mendel intends to syn-
thesize chemicals that
regulate relevant tran-
scription factors that can
be delivered as a crop
spray to mitigate environ-
mental stressors and
modify the growth cycle.
Chemical genetics borrows much
from classical genetics, which relies
on mutations. However, in classical
genetics, if a mutation is lethal, it
will kill your plant, but you may not
know why. Chemical genetics
allows a remarkable degree of con-
trol, including dose amount and
treatment time that is unavailable in
mutational screens. Moreover, it
enables you to investigate genes
that are redundant [1].
Under the Watchful Eye of Zeus
Mendel Biotechnology, Inc. (www.
mendelbio.com), is located in a Hay-
ward, California office park improb-
ably adorned with white-washedstatues of Greek gods and nymphs.
They came with the place, com-
mented Neal Gutterson, Ph.D., Men-
del’s president and chief operating
officer. Gutterson is no stranger to
the fantastic. His prior company
sought to develop a blue rose, a hor-
ticulturally glamorous feat, but not
a particularly lucrative one. ‘‘You
will never get enough money back
from selling blue roses to justify the
ungodly amount of money that
went into producing them,’’ Gutter-
son said. Mendel Biotechnology,
on the other hand, concentrates on
major commercial crops and uses
Arabidopsis thaliana, the prosaic
workhorse of plant genetics, for its
research. ‘‘We think a lot about
what is really worth doing from a
business standpoint.’’ Gutterson
said. Mendel’s warehouse-like labo-
ratories house several temperature-
controlled chambers stacked with
trays of Arabidopsis seedlings, as
the plants like it cool.
The 55 person company, founded
in 1997, is privately held. It has
raised $12 million in equity, but
has supported itself since its incep-
tion through funded collaborative
research mostly for Monsanto,
which owns a small equity stake in
Mendel.
Agriculture changes at a stately
pace. Mendel looks for trend-
insensitive crops to balance their
revenue cycles. ‘‘There is not a thing
that we do that takes less than eight
years to reach the market,’’ Gutter-
son says, ‘‘Improved yield in corn
is going to be desirable for a long
time to come.’’ Mendel recently
started growing varieties of poplar,
switchgrass, and miscanthus for
cellulosic ethanol.
About three and a half years ago,
Mendel inaugurated a program in
chemical genetics. ‘‘We recognized
that there were crops for which
genetic solutions would be very
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son said. ‘‘People aren’t going to be
tearing out their cabernet vineyards
to plant [genetically engineered]
grapevines anytime soon.’’ Mendel
intends to synthesize chemicals
that regulate relevant transcription
factors that can be delivered as
a crop spray to mitigate environ-
mental stressors and modify the
growth cycle. For example, if
a heat spell is predicted in spring
when avocado trees are blossom-
ing, farmers can spray them with
an agent to keep them from drop-
ping their flowers. Growth hormones
have been used in agriculture for de-
cades, but while hormones affect
plant biology broadly, Mendel’s
chemical regulation of genetic tran-
scription factors represents a more
targeted approach.
Follow the Biochemical Pathways
Arabidopsis has 27,000 genes,
which are potentially regulated by
1,800 transcription factors. Accord-
ing to the company, all the genes
responsible for a particular plant
function or biochemical pathway
can typically be controlled by a
single transcription factor. This in-
cludes complex traits like the ability
to withstand extreme conditions,
disease resistance, and nitrogen de-
pendency. According to Gutterson,
the company is looking for small
molecules that can upregulate a par-
ticular transcription pathway and
thus be used as a ‘‘switch’’ to mod-
ulate its activity. ‘‘Really, in the last
couple of years, we have worked
on proof of principle, identifying
pathways we know a lot about in
Arabidopsis through our genomics
program and then identifying
chemistry that regulates these path-
ways,’’ said Joshua Armstrong,
Ph.D., researcher in chemical genet-
ics at Mendel.
However, a small molecule may
work differently on natural variants
within a population than it does on
laboratory strains, so translation
from the lab to the field may not be
straightforward. Potential compli-
cating issues include compound
metabolism, target binding, and
specificity. Uptake of the compound
needs to be considered, as well
as toxicity and bioaccumulation
issues. Another concern is that
changing one variable can influence
another; for example, impartingdrought resistance to a plant can
make it grow more slowly. Pathways
may also overlap, such as the ones
for freezing and dehydration, in
such a way that it may be hard to
implement a program for a particular
trait.
Mendel expects to submit their
chemicals to the Environmental Pro-
tection Agency for approval in what
will probably be a process similar
to those for other agricultural chem-
icals. According to Gutterson, ma-
nipulating plants through chemistry
could be cheaper than modifying
plants transgenically since the
chemistry is potentially applicable
to many different crops, each of
which would have to be individually
genetically modified. Mendel is
also working on chemical regulation
of disease pathways by activating
plants’ innate immunity pathways
as well as reducing crop require-
ments for nitrogen. However, ‘‘the
holy grail of getting plants like corn
to make their own nitrogen is
a long way off,’’ said Gutterson.
Ceres Cultivates Drugs
Ceres, Inc. (www.ceres.net), in
Thousand Oaks, California, lacks
the mythological lawn statues, but
is named for the Roman goddess
of agriculture. Since 2002, Ceres
has been developing corn and soy-
beans for traits including enhanced
yield, stress resistance, and more
efficient nitrogen utilization as part
of a $137 million license-based
agreement with Monsanto. The
privately held company engineers
energy crops as well. Ceres is also
using plants to produce clinically
relevant compounds like taxol, arte-
mesinin, and derivatives of opiates.
‘‘We are a functional genomics
company, and we are engineering
metabolic pathways in plants to pro-
duce plant-derived drugs more
efficiently,’’ said Dr. Steven Bobzin,
director of natural products chemis-
try. To do this, Ceres identifies the
genes that encode biosynthetic
enzymes in plants that produce the
desired compounds and manipu-
lates them. Ceres is specific in its
focus. ‘‘We are not proposing to
put pharmaceuticals in corn flakes,’’
Bobzin says, ‘‘we are producing
small molecules in the biosynthetic
pathway.’’
According to Bobzin, Ceres owes
its progress to the advancement ingenetic sequencing capacity. He
cites the example of taxol, an expen-
sive compound produced from yew.
‘‘We can increase the yield signifi-
cantly.within the plant,’’ said Bob-
zin. According to Bobzin, the com-
pany has already identified some of
the genes involved in the biosyn-
thesis of taxol and is on the way to
identifying the rest. Once com-
pleted, those genes will be trans-
ferred to another plant that will serve
as a biosynthetic platform for pro-
duction of large amounts of material
in a more cost-effective way. Other
genetically engineered candidates
in the pipeline include opiate deriva-
tives that will not cross the blood-
brain barrier. Ceres does this by
manipulating environmental condi-
tions, as certain stresses improve
yield. The company also uses trans-
genic approaches to express a
targeted molecule in all tissues of
the plant.
But there is still much to discover.
‘‘There are going to be cases where
these things don’t work,’’ said Glenn
Hicks, Ph.D., associate research
plant cell biologist, who works in
collaboration with Dr. Natasha
Raikhel at the Center for Plant Cell
Biology (CEPCEB) at the University
of California, Riverside. ‘‘Evolution
being what it is, there are going to
be fundamental similarities between
all plant species, but when it comes
down to it, there are going to be
some differences.’’ According to
Hicks, while genes involved in the
biosynthesis of specialized metabo-
lites might not translate from Arabi-
dopsis to maize, properties such as
stress tolerance or photosynthesis
are more fundamental and could
equally apply to all plants.
Companies like Mendel and Ceres
can develop compounds to proof of
concept stage, but will partner with
a major agricultural company like
Monsanto for the resources needed
for commercialization, Hicks said,
because proof of concept is a small
percentage of the total costs of de-
velopment and commercialization.
‘‘The agricultural industry went
through this chemical boom in the
70s and 80s where everyone was
interested in growth regulators and
adding hormones to plants and en-
hancing yield,’’ said Hicks. ‘‘A lot of
it turned out to be a bust.’’ Accord-
ing to Hicks, now, particularly as
biotechnology advances are being
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ality of some of the advances in ge-
nomics and automated chemistry
is settling in, and although these
approaches will not resolve all of
our challenges, they are going to re-
sult in some great advances.’’
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